UB Paderborn / Katalog / Suche / in CDI

Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study

Haematologica (Roma), 2024-02, Vol.109 (2), p.553

2024

Link zum Volltext

Verfügbarkeit prüfen

PB2304: FIVE‐YEAR SUBGROUP ANALYSIS OF TAFASITAMAB + LENALIDOMIDE FROM THE PHASE II L‐MIND STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

HemaSphere, 2023-08, Vol.7 (S3), p.e7389505-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

P1138: FIVE‐YEAR EFFICACY AND SAFETY OF TAFASITAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY DLBCL: FINAL RESULTS FROM THE PHASE II L‐MIND STUDY

HemaSphere, 2023-08, Vol.7 (S3), p.e4580941-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

P1A Recombinant β-Lactamase Prevents Emergence of Antimicrobial Resistance in Gut Microflora of Healthy Subjects during Intravenous Administration of Ampicillin

Antimicrobial Agents and Chemotherapy, 2009-06, Vol.53 (6), p.2455-2462

2009

Link zum Volltext

Verfügbarkeit prüfen

Five-year subgroup analysis of tafasitamab + lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e19522-e19522

2023

Link zum Volltext

Verfügbarkeit prüfen

L-Mind: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Receiving Treatment for at Least 2 Years

Blood, 2022-11, Vol.140 (Supplement 1), p.6596-6598

2022

Link zum Volltext

Verfügbarkeit prüfen

ABCL-482 Five-Year Subgroup Analysis of Tafasitamab + Lenalidomide From the Phase II L-MIND Study in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S436-S437

2023

Link zum Volltext

Verfügbarkeit prüfen

POSTER: ABCL-450 Five-Year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results From the Phase II L-MIND Study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S206-S206

2023

Link zum Volltext

Verfügbarkeit prüfen

POSTER: ABCL-482 Five-Year Subgroup Analysis of Tafasitamab + Lenalidomide From the Phase II L-MIND Study in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S206-S206

2023

Link zum Volltext

Verfügbarkeit prüfen

ABCL-450 Five-Year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results From the Phase II L-MIND Study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S433-S434

2023

Link zum Volltext

Verfügbarkeit prüfen

ABCL-388 L-MIND: Safety and Efficacy of Tafasitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma on Treatment for at Least 2 Years

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S375

2022

Link zum Volltext

Verfügbarkeit prüfen

Poster: ABCL-388 L-MIND: Safety and Efficacy of Tafasitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma on Treatment for at Least 2 Years

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S164

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT022: Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the phase II L-MIND study

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT022-CT022

2023

Link zum Volltext

Verfügbarkeit prüfen

Involvement of Rho kinase pathway in the mechanism of renal vasoconstriction and cardiac hypertrophy in rats with experimental heart failure

American journal of physiology. Heart and circulatory physiology, 2006-05, Vol.59 (5), p.H2007

2006

Link zum Volltext

Verfügbarkeit prüfen

P1A Recombinant ?-Lactamase Prevents Emergence of Antimicrobial Resistance in Gut Microflora of Healthy Subjects during Intravenous Administration of Ampicillin

Antimicrobial agents and chemotherapy, 2009-06, Vol.53 (6), p.2455-2462

2009

Link zum Volltext

Verfügbarkeit prüfen

Differential regulation of renal regional blood flow by endothelin-1

American journal of physiology. Renal physiology, 1996-12, Vol.271 (6), p.1166-F1172

1996

Link zum Volltext

Verfügbarkeit prüfen

Involvement of Rho kinase pathway in the mechanism of renal vasoconstriction and cardiac hypertrophy in rats with experimental heart failure

American journal of physiology. Heart and circulatory physiology, 2006-05, Vol.290 (5), p.H2007-H2014

2006

Link zum Volltext

Verfügbarkeit prüfen

Regulation of intrarenal blood flow in experimental heart failure: role of endothelin and nitric oxide

American journal of physiology. Renal physiology, 1998-04, Vol.274 (4), p.F766-F774

1998

Link zum Volltext

Verfügbarkeit prüfen

Effects of Eprosartan on Renal Function and Cardiac Hypertrophy in Rats With Experimental Heart Failure

Hypertension (Dallas, Tex. 1979), 1998-10, Vol.32 (4), p.746-752

1998

Link zum Volltext

Verfügbarkeit prüfen

Impaired nitric oxide-mediated renal vasodilation in rats with experimental heart failure : Role of angiotensin II

Circulation (New York, N.Y.), 1997-11, Vol.96 (10), p.3655-3664

1997

Link zum Volltext

Verfügbarkeit prüfen

Urinary neutral endopeptidase 24.11 activity: Modulation by chronic salt loading

Kidney international, 1995-03, Vol.47 (3), p.855-860

1995

Link zum Volltext

Verfügbarkeit prüfen

Impaired nitric oxide-mediated renal vasodilation in rats with experimental heart failure

Circulation (New York, N.Y.), 1997-11, Vol.96 (10), p.3655

1997

Link zum Volltext

Verfügbarkeit prüfen

Bosentan improves renal regional blood flow in rats with experimental congestive heart failure

European journal of pharmacology, 1996-08, Vol.310 (2), p.193-196

1996

Link zum Volltext

Verfügbarkeit prüfen

Differential regulation of renal regional blood flow by endothelin-1

American journal of physiology. Renal physiology, 1996-12, Vol.40 (6), p.F1166

1996

Link zum Volltext

Verfügbarkeit prüfen

Differential Effect of Endothelin-1 on Renal Regional Blood Flow: Role of Nitric Oxide

Journal of cardiovascular pharmacology, 1995, Vol.26 Suppl 3, p.S208-210

1995

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study

PB2304: FIVE‐YEAR SUBGROUP ANALYSIS OF TAFASITAMAB + LENALIDOMIDE FROM THE PHASE II L‐MIND STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

P1138: FIVE‐YEAR EFFICACY AND SAFETY OF TAFASITAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY DLBCL: FINAL RESULTS FROM THE PHASE II L‐MIND STUDY

P1A Recombinant β-Lactamase Prevents Emergence of Antimicrobial Resistance in Gut Microflora of Healthy Subjects during Intravenous Administration of Ampicillin

Five-year subgroup analysis of tafasitamab + lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma

L-Mind: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Receiving Treatment for at Least 2 Years

ABCL-482 Five-Year Subgroup Analysis of Tafasitamab + Lenalidomide From the Phase II L-MIND Study in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

POSTER: ABCL-450 Five-Year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results From the Phase II L-MIND Study

POSTER: ABCL-482 Five-Year Subgroup Analysis of Tafasitamab + Lenalidomide From the Phase II L-MIND Study in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

ABCL-450 Five-Year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results From the Phase II L-MIND Study

ABCL-388 L-MIND: Safety and Efficacy of Tafasitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma on Treatment for at Least 2 Years

Poster: ABCL-388 L-MIND: Safety and Efficacy of Tafasitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma on Treatment for at Least 2 Years

Abstract CT022: Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the phase II L-MIND study

Involvement of Rho kinase pathway in the mechanism of renal vasoconstriction and cardiac hypertrophy in rats with experimental heart failure

P1A Recombinant ?-Lactamase Prevents Emergence of Antimicrobial Resistance in Gut Microflora of Healthy Subjects during Intravenous Administration of Ampicillin

Differential regulation of renal regional blood flow by endothelin-1

Involvement of Rho kinase pathway in the mechanism of renal vasoconstriction and cardiac hypertrophy in rats with experimental heart failure

Regulation of intrarenal blood flow in experimental heart failure: role of endothelin and nitric oxide

Effects of Eprosartan on Renal Function and Cardiac Hypertrophy in Rats With Experimental Heart Failure

Impaired nitric oxide-mediated renal vasodilation in rats with experimental heart failure : Role of angiotensin II

Urinary neutral endopeptidase 24.11 activity: Modulation by chronic salt loading

Impaired nitric oxide-mediated renal vasodilation in rats with experimental heart failure

Bosentan improves renal regional blood flow in rats with experimental congestive heart failure

Differential regulation of renal regional blood flow by endothelin-1

Differential Effect of Endothelin-1 on Renal Regional Blood Flow: Role of Nitric Oxide

Suchergebnisse filtern